IL-2 gene therapy (VIB/KU Leuven)

N/A

Report date: 2025/01/26 18:48:25

Base Information

Drug NameIL-2 gene therapy (VIB/KU Leuven)
Drug Alias NameAAV vector-based gene therapy (VIB/KU Leuven)
ClassificationBiologics
Mechanisms of ActionIL2 gene transference
TargetsInterleukin-2
Therapy Area/IndicationsCentral Nervous System Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFlanders Institute for Biotechnology VZW
China Registration ClassN/A

Develop Information

Active CompaniesFlanders Institute for Biotechnology VZWKu Leuven
Inactive CompaniesN/A
Active IndicationsCentral Nervous System Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A